# Effects of Nattokinase on Cardiovascular Risk, Gut Microbiota, Sleep, and Cognition in Metabolic Syndrome With Sleep Disorders.

> **NCT07229521** · NA · RECRUITING · sponsor: **Taipei Medical University** · enrollment: 80 (estimated)

## Conditions studied

- Metabolic Syndrome
- Sleeping Disorders

## Interventions

- **DIETARY_SUPPLEMENT:** Nattokinase
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07229521
- **Lead sponsor:** Taipei Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-15
- **Primary completion:** 2026-12-11
- **Final completion:** 2027-02-11
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07229521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07229521, "Effects of Nattokinase on Cardiovascular Risk, Gut Microbiota, Sleep, and Cognition in Metabolic Syndrome With Sleep Disorders.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07229521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*